tbuckley/cabot-search huggingface dataset:
Impact of county-level surgical specialist density on breast (BrCa) and lung cancer (LuCa) mortality.
Authors: Andrei Karpov, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2012)

6064 Background: Variations in distribution of the surgical workforce may result in differential access to cancer screening and treatment. Our aim was to explore the relationship between county-level surgical specialist density and BrCa and LuCa mortality. Methods: Using data from Area Resource File, US Census and National Cancer Institute, regression models that controlled for cancer incidence, county demographics and socioeconomic factors were constructed to examine the association among a) general surgeon (GS) and radiation oncologist (RO) density with BrCa mortality and b) thoracic surgeon (ThS) and RO density with LuCa mortality. Plastic (PS) and transplant surgeons (TrS) were used as surgical controls as they were not expected to correlate significantly with BrCa or LuCa mortality. Results: A total of 1,557 and 2,044 US counties were analyzed for BrCa and LuCa, respectively: mean incidences were 119 and 75 and death rates were 25 and 59 per 100,000 people, respectively, for BrCa and LuCa. Mean specialist densities were 7.72 (GS), 0.80 (RO), and 0.97 (PS) [for BrCa counties] and 0.55 (ThS), 0.55 (RO), and 0.01 (TrS) [for LuCa counties] per 100,000. When compared to counties with no surgical specialist, those with at least one GS and RO for BrCa and at least one ThS and RO for LuCa were associated with decreased mortality (Table). Increasing the density of GS and RO beyond 9 and 1 per 100,000 did not result in significant reductions in BrCa mortality. Likewise, increasing the density of ThS and RO to above 1 each per 100,000 failed to yield further improvements in LuCa mortality. Counties with more elderly residents also correlated with worse BrCa and LuCa outcomes. Conclusions: The presence of specific surgical specialists is associated with lower BrCa and LuCa mortality. There appears to be a threshold at which point further increase in their density do not contribute to continued improvements in outcomes. Distributing the surgical workforce across all counties will offer population-based improvements in BrCa and LuCa mortality. [Table: see text]
PREDICTORS OF CALCIFIC AORTIC VALVE STENOSIS PROGRESSION AS MEASURED BY CHANGE IN MEAN PRESSURE GRADIENT: A META-ANALYSIS AND META-REGRESSION
Authors: Navneet Sharma, Sareena George, Ramsey Kalil, Prateek Sharma, Paul Kim, Clive Goulbourne, Smadar Kort, Dmitriy Feldman, Puja Parikh
Journal: Journal of the American College of Cardiology (2020)
Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
Authors: Marshall S. Goodwin, Cara L. Croft, Hunter S. Futch, Daniel Ryu, Carolina Ceballos-Diaz, Xuefei Liu, Giavanna Paterno, Catalina Mejia, Doris Deng, Kimberly Menezes, Laura Londono, Kefren Arjona, Mary Parianos, Van Truong, Eva Rostonics, Amanda Hernandez, Sanford L. Boye, Shannon E. Boye, Yona Levites, Pedro E. Cruz, Todd E. Golde
Journal: Molecular Neurodegeneration (2020)

Abstract Background Recombinant adeno-associated virus (rAAV) is widely used in the neuroscience field to manipulate gene expression in the nervous system. However, a limitation to the use of rAAV vectors is the time and expense needed to produce them. To overcome this limitation, we evaluated whether unpurified rAAV vectors secreted into the media following scalable PEI transfection of HEK293T cells can be used in lieu of purified rAAV. Methods We packaged rAAV2-EGFP vectors in 30 different wild-type and mutant capsids and subsequently collected the media containing secreted rAAV. Genomic titers of each rAAV vector were assessed and the ability of each unpurified virus to transduce primary mixed neuroglial cultures (PNGCs), organotypic brain slice cultures (BSCs) and the mouse brain was evaluated. Results There was ~ 40-fold wide variance in the average genomic titers of the rAAV2-EGFP vector packaged in the 30 different capsids, ranging from a low ~ 4.7 × 10 10 vector genomes (vg)/mL for rAAV2/5-EGFP to a high of ~ 2.0 × 10 12 vg/mL for a capsid mutant of rAAV2/8-EGFP. In PNGC studies, we observed a wide range of transduction efficiency among the 30 capsids evaluated, with the rAAV2/6-EGFP vector demonstrating the highest overall transduction efficiency. In BSC studies, we observed robust transduction by wild-type capsid vectors rAAV2/6, 2/8 and 2/9, and by capsid mutants of rAAV2/1, 2/6, and 2/8. In the in vivo somatic brain transgenesis (SBT) studies, we found that intra-cerebroventricular injection of media containing unpurified rAAV2-EGFP vectors packaged with select mutant capsids resulted in abundant EGFP positive neurons and astrocytes in the hippocampus and forebrain of non-transgenic mice. We demonstrate that unpurified rAAV can express transgenes at equivalent levels to lysate-purified rAAV both in vitro and in vivo. We also show that unpurified rAAV is sufficient to drive tau pathology in BSC and neuroinflammation in vivo , recapitulating previous studies using purified rAAV. Conclusions Unpurified rAAV vectors secreted into the media can efficiently transduce brain cells in vitro and in vivo, providing a cost-effective way to manipulate gene expression. The use of unpurified virus will greatly reduce costs of exploratory studies and further increase the utility of rAAV vectors for standard laboratory use.
IN-HOSPITAL STROKE AFTER TAVR AND SAVR IN RENAL TRANSPLANT PATIENTS
Authors: Omar Abdelfattah, Anas Saad, Mohamed Hassanein, Toshiaki Isogai, Keerat Rai Ahuja, Mohamed M. Gad, Shashank Shekhar, Manpreet Kaur, Mohamed Diab, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)
Sugar-Induced Obesity and Insulin Resistance Are Uncoupled from Shortened Survival in Drosophila
Authors: Esther van Dam, Lucie A.G. van Leeuwen, Eliano dos Santos, Joel James, Lena Best, Claudia Lennicke, Alec J. Vincent, Georgios Marinos, Andrea Foley, Marcela Buricova, Joao B. Mokochinski, Holger B. Kramer, Wolfgang Lieb, Matthias Laudes, Andre Franke, Christoph Kaleta, Helena M. Cochemé
Journal: Cell Metabolism (2020)

High-sugar diets cause thirst, obesity, and metabolic dysregulation, leading to diseases including type 2 diabetes and shortened lifespan. However, the impact of obesity and water imbalance on health and survival is complex and difficult to disentangle. Here, we show that high sugar induces dehydration in adult Drosophila, and water supplementation fully rescues their lifespan. Conversely, the metabolic defects are water-independent, showing uncoupling between sugar-induced obesity and insulin resistance with reduced survival in vivo. High-sugar diets promote accumulation of uric acid, an end-product of purine catabolism, and the formation of renal stones, a process aggravated by dehydration and physiological acidification. Importantly, regulating uric acid production impacts on lifespan in a water-dependent manner. Furthermore, metabolomics analysis in a human cohort reveals that dietary sugar intake strongly predicts circulating purine levels. Our model explains the pathophysiology of high-sugar diets independently of obesity and insulin resistance and highlights purine metabolism as a pro-longevity target.
Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy with a modified dose schedule: Retrospective analysis of a single institutional experience
Authors: T. Toita, W. Tamaki, T. Maehama, K. Ogawa, Y. Nagai, S. Iraha, Y. Kakinohana, H. Moromizato, K. Kanazawa, S. Murayama
Journal: Journal of Clinical Oncology (2006)

15019 Background: The purpose of this study was to assess the effectiveness of concurrent chemoradiotherapy (CCRT) using high-dose-rate intracavitary brachytherapy (HDR-ICBT) with a dose schedule modified from the American Brachytherapy Society (ABS) recommendation. Methods: 68 consecutive patients (IB2: 3, IIA: 2, IIB: 32, and IIIB: 31) with cervical squamous cell carcinoma consecutively treated with CCRT using HDR-ICBT were retrospectively analyzed. Patients with para-aortic lymphadenopathy (greater than 10mm in minimum diameter assessed by CT) were excluded. The median tumor size (assessed by MRI) was 60mm (range: 40–86mm). Cisplatin (20 mg/m 2 /day) was concurrently administered with radiotherapy (RT) for 5 days at 21-day intervals for a median of 2 courses (range: 1–5). The planned RT schedule consisted of pelvic external beam RT (EBRT) with 40Gy/20 fractions followed by HDR-ICBT with 18Gy/3 fractions and pelvic EBRT with 10Gy/5 fractions using a midline block (MB). The cumulative biologically effective dose (BED) at point A of this schedule was 77Gy10. 60 patients (88%) were treated with this schedule. In the remaining 8 patients, pelvic EBRT was delivered without MB (up to 50Gy), and/or additional HDR-ICBT (up to 24Gy) was given. The actual BED for all 68 patients thus ranged from 77 to 89 Gy10. Median follow-up of the surviving 54 patients was 46 months (range: 8–91 months). Late complications were graded by the RTOG/EORTC criteria. Results: The actuarial overall survival rate, disease-free survival rate, and pelvic control rate at 4 years were 78% (95% CI, 68–90%), 74% (95% CI, 63–85%), and 90% (95% CI, 83–97%), respectively. Only one patient suffered a grade 3 complication (enterocolitis). The actuarial late complication (Grade 1or higher) rates at 4 years were 12% (95% CI, 3–20%) for proctitis, 2% (95% CI, 0–5%) for cystitis, and 21% (95% CI, 10–33%) for enterocolitis. Conclusions: This retrospective analysis suggests that CCRT using HDR-ICBT with a modified dose schedule was able to achieve favorable pelvic disease control without severe late complications for patients with cervical cancer. No significant financial relationships to disclose.
Clinical Usefulness of ΔMELD to Predict the Survival of Patients with Liver Cirrhosis
Authors: 은수훈, 김연수, Jang Jae Young, Young Koog Cheon, Young Seok Kim, 조영덕, 이준성, 이문성, 김주현, 심찬섭, Boo Sung Kim
Journal: Clinical and Molecular Hepatology (2006)
HELPER T CELLS INFILTRATING THE AORTIC MEDIA ARE ASSOCIATED WITH AORTIC DISSECTION IN PATIENTS WITH A BICUSPID AORTIC VALVE
Authors: Alexander Staal, Kim R.G. Cortenbach, Mark A.J. Gorris, Guillaume S.C. Geuzebroek, Lambert J. Wisse, Mangala Srinivas, Wim J. Morshuis, I Jolanda M. de Vries, Marco C. de Ruiter, Roland R.J. van Kimmenade
Journal: Journal of the American College of Cardiology (2020)
Ibrutinib suppresses intracellular mycobacterium tuberculosis growth by inducing macrophage autophagy
Authors: Yunlong Hu, Zhihua Wen, Song Liu, Yi Cai, Jiubiao Guo, Yuzhong Xu, Dachuan Lin, Jialou Zhu, Dechang Li, Xinchun Chen
Journal: Journal of Infection (2020)
ANATOMICAL SEVERITY OF INFRAPOPLITEAL LESIONS STRATIFIED BY GLOBAL LIMB ANATOMIC STAGING SYSTEM (GLASS) DOSE NOT IMPACT ON WOUND HEALING IN PATIENTS WITH CHRONIC LIMB-THREATENING ISCHEMIA
Authors: Sho Nakao, Osamu Iida, Mitsutoshi Asai, Masaharu Masuda, Shin Okamoto, Takayuki Ishihara, Kiyonori Nanto, Takashi Kanda, Takuya Tsujimura, Shota Okuno, Yasuhiro Matsuda, Yosuke Hata, Hiroyuki Uematsu, Yuki Sato, Hiroki Sugae, Shodai Kawanami, Toshiaki Mano
Journal: Journal of the American College of Cardiology (2020)
EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL
Authors: Zien Zhou, Meg Jardine, Qiang Li, Richard Lindley, Brendon Neuen, Christopher P. Cannon, Dick De Zeeuw, Robert Edwards, Tom Greene, Adeera Levin, Kenneth Mahaffey, Vlado Perkovic, Bruce Neal
Journal: Journal of the American College of Cardiology (2020)
THE IMPACT OF INSUFFICIENT MITRAL LEAFLET REMODELING RELATIVE TO ANNULAR DILATION ON RESIDUAL MITRAL REGURGITATION AFTER TRANSCATHETER MITRAL REPAIR
Authors: Kensuke Hirasawa, Farnaz Namazi, Stephan Milhorini Pio, Ngoc Mai Vo, Nina Ajmone Marsan, Jeroen Bax, Victoria Delgado
Journal: Journal of the American College of Cardiology (2020)
ASSOCIATION BETWEEN ORBITAL OR ROTATIONAL ATHERECTOMY AND CLINICAL OUTCOMES AMONG PATIENTS WITH CALCIFIC CORONARY ARTERY DISEASE: INSIGHTS FROM THE CLINICAL ASSESSMENT, REPORTING AND TRACKING (CART) PROGRAM
Authors: Christopher Barrett, Christopher Kovach, Erin McGuinn, Ehrin J. Armstrong, Stephen W. Waldo
Journal: Journal of the American College of Cardiology (2020)
Are breast cancers in India different from Western populations? Results of a tertiary center retrospective analysis.
Authors: Sayan Chakraborty, Sandip Sarkar, Namrata Agarwal, Rosina Ahmed, Sanjoy Chatterjee, Indranil Ghosh
Journal: Journal of Clinical Oncology (2013)

e12039 Background: Breast cancer is the commonest cancer in the urban Indian female population but comprehensive data on the details of tumor types, outcomes post treatment and comparison with Western data is not readily available. We present a robust database of Eastern Indian breast cancers reported from a tertiary center. Methods: Retrospective analysis of 407 unselected medical records of breast cancer cases between June 2011 and October 2012 were undertaken. Clinico-pathological details, Nottingham Prognostic Index (NPI) Score post surgery (conservation and mastectomy) and follow-up were analyzed. Adjuvant chemotherapy details were recorded. Following Institutional guidelines a hypofractionated Radiotherapy (RT) schedule was delivered (40Gy in 15 Fractions over 3 weeks), with boost delivered in patients receiving conservation surgery. Acute radiation toxicity following hypofractionation was recorded. Results: Mean age at presentation was 52.42 years. 383 (94%) underwent surgery; breast-conservation in 37%. 34% received neo-adjuvant anthracycline-taxane sequential chemotherapy prior to surgery. For those who underwent upfront surgery, 12% patients had pT3 disease and 83% pT1/T2. 41%, 31%, 16% and 12% had pN0, N1, N2 and N3 disease respectively. 89% cases had infiltrating ductal carcinoma with 57% Grade III disease. 73% were ER positive and 35% were Her-2 positive. 31% patients were intermediate risk and 36% high risk (&gt;5.5) by NPI Score. After upfront surgery 54% received adjuvant chemotherapy of which 63% received both anthracycline and taxanes sequentially. 67.4% patients received adjuvant RT where the median time between date of surgery and starting of RT was 5 months. Median post hypofractionated RT follow-up was 6 months when 7 out of 97 patients had &gt; Grade 0 Skin toxicity, 4 had breast edema, 6 shrinkage, 8 patients had Grade I Lymphedema. Conclusions: Indian patients were younger and had advanced stage at presentation and higher NPI scores requiring more combined systemic chemotherapy. Hypofractionated RT schedule was tolerated well and further hypofractionation could now be investigated in clinical studies to improve throughput in moderate resource countries like India.
CONCOMITANT DILATED CARDIOMYOPATHY WITH SUPERIOR VENA CAVA THROMBOSIS AS INITIAL PRESENTATIONS FOR BEHCET’S DISEASE
Authors: Ahmed Elzanaty, Ebrahim Sabbagh, Mohammed Awad, Zeid Nesheiwat, Eman Elsheikh, Basil Akpunonu, Moshrik AbdAlamir
Journal: Journal of the American College of Cardiology (2020)
Molecular staging with CM10 ProteinChip and SELDI-MS-TOF for colorectal cancer patients before surgery
Authors: Y. Chen, W. Xu, S. Zheng, S. Zhang
Journal: Journal of Clinical Oncology (2006)

3612 Background: The objectives of this are to detect the serum proteomic patterns by using SELDI-TOF-MS technology and CM10 ProteinChip in colorectal cancer (CRC) patients, and to evaluate the significance of the proteomic patterns in the tumor staging of colorectal cancer. Methods: SELDI-TOF-MS and CM10 ProteinChip were used to detect the serum proteomic patterns of 76 colorectal cancer patients which including 10 Stage I, 19 Stage II, 16 Stage III and 31 Stage IV patients. Models for various stages were developed and validated by using Support Vector Machine, Discriminant Analysis and time-series analysis methods. Results: The first model, formed by 6 protein peaks (M/Z: 2759.58, 2964.66, 2048.01, 4795.90, 4139.77 and 37761.60 Da), could be used to distinguish local CRC patients (StageIand Stage II) from regional CRC patients (Stage III) with an accuracy of 86.67% (39/45). The second model, formed by 3 protein peaks (M/Z: 6885.30, 2058.32 and 8567.75 Da), could be used to distinguish locoregional CRC patients (Stage I,Stage II and Stage III) from systematic CRC patients (Stage IV) with an accuracy of 75.00% (57/76). The third model could distinguish Stage I from Stage II with an accuracy of 86.21% (25/29). The fourth model could distinguish Stage I from Stage III with an accuracy of 84.62% (22/26). The fifth model could distinguish Stage II from Stage III with an accuracy of 85.71% (30/35). The sixth model could distinguish Stage II from Stage IV with an accuracy of 80.00% (40/50). The seventh model could distinguish Stage III from Stage IV with an accuracy of 78.72% (37/47). All four stages could be distinguished by using a two-dimensional scattered spots figure. Conclusion: We conclude that this method is promising in the staging of colorectal cancer patients before surgery. No significant financial relationships to disclose.
EFFECT OF QT PROLONGATION ON VENTRICULAR ARRHYTHMIAS AND CARDIAC ARREST FOLLOWING LIVER TRANSPLANTATION
Authors: Jefferson Ko, Anoop Koshy, H.M. Omar Farouque, Paul Gow, Hui-Chen Han, Benjamin Cailes, Anees Enayati, Laurence Weinberg, Adam Testro, Han Lim, Andrew Teh
Journal: Journal of the American College of Cardiology (2020)
CHARACTERIZATION, TREATMENT AND OUTCOMES OF PATIENTS WITH STABLE ISCHEMIC HEART DISEASE IN A TERTIARY-CARE CENTER IN BRAZIL
Authors: Eduardo Moreira, Cibele Garzillo, Sandra Ayres, Desiderio Favarato, Fabio Pitta, Eduardo Gomes Lima, Whady Hueb, Carlos Serrano
Journal: Journal of the American College of Cardiology (2020)
VENTRICULAR ARRHYTHMIAS MOST LIKELY TO OCCUR IN THE IMMEDIATE POST-DIALYSIS PERIOD IN PATIENTS WITH END-STAGE RENAL DISEASE AND CARDIAC IMPLANTABLE ELECTRONIC DEVICES
Authors: Evan Harmon, Brittney Heard, Spiro Stilianoudakis, Sula Mazimba, Brendan Bowman, Nishaki Mehta
Journal: Journal of the American College of Cardiology (2020)
PROGNOSTIC IMPACT OF INTRAPLAQUE HEMORRHAGE WITH CHOLESTEROL CRYSTALS IN NON-CULPRIT LESIONS ASSESSED BY OPTICAL COHERENCE TOMOGRAPHY
Authors: Eisuke Usui, Gary Mintz, Tetsumin Lee, Mitsuaki Matsumura, Masahiro Hada, Masao Yamaguchi, Masahiro Hoshino, Yoshihisa Kanaji, Tomoyo Sugiyama, Tadashi Murai, Taishi Yonetsu, Tsunekazu Kakuta, Akiko Maehara
Journal: Journal of the American College of Cardiology (2020)
IS PRE-EXISTING PULMONARY HYPERTENSION A PREDICTOR OF LEFT VENTRICLE SYSTOLIC FUNCTION AND FUNCTIONAL OUTCOMES AMONG PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT?
Authors: Andrew S. Begg, Garima Dahiya, Andreas Kyvernitakis, Mark Doyle, David Lasorda, Stephen Bailey, Amresh Raina, Robert Biederman, Raymond Benza
Journal: Journal of the American College of Cardiology (2020)
PHENOPROFILING CARDIOGENIC SHOCK: A REPORT FROM THE CARDIOGENIC SHOCK WORKING GROUP
Authors: Katherine Thayer, Elric Zweck, Mohyee Ayouty, Ole K.L. Helgestad, Jakob Josiassen, Daniel Burkhoff, Arthur R. Garan, Jaime Hernandez Montfort, Claudius Mahr, Jacob Eifer Møller, Navin Kapur
Journal: Journal of the American College of Cardiology (2020)
REGIONAL REPLACEMENT AND DIFFUSE INTERSTITIAL LEFT VENTRICULAR FIBROSIS IN CHRONIC AORTIC VALVE REGURGITATION: INSIGHTS AND PROGNOSTIC IMPLICATIONS FROM CARDIAC MAGNETIC RESONANCE
Authors: Alpana Senapati, Maan Malahfji, Dany Debs, Eric Yota Yang, Duc T. Nguyen, Edward Graviss, Dipan J. Shah
Journal: Journal of the American College of Cardiology (2020)
CLO20-039: Patient (pt)-Reported Outcomes (PRO) in Patients With HER2-Negative Locally Advanced/Metastatic Breast Cancer (LA/mBC) and a Germline BRCA1/2 Mutation (gBRCA1/2 mut) Receiving Talazoparib vs. Physician’s Choice of Chemotherapy (PCT): A Focus on EMBRACA Racial Subgroups
Authors: Sara A. Hurvitz, Ruben G. W. Quek, Helen Bhattacharyya, Johannes Ettl, Anthony Gonçalves, Hope S. Rugo
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-039: Patient (pt)-Reported Outcomes (PRO) in Patients With HER2-Negative Locally Advanced/Metastatic Breast Cancer (LA/mBC) and a Germline BRCA1/2 Mutation (gBRCA1/2 mut) Receiving Talazoparib vs. Physician’s Choice of Chemotherapy (PCT): A Focus on EMBRACA Racial Subgroups" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Nonmyeloablative allogeneic blood stem cell transplantation (NMBSCT) ± donor lymphocyte infusion (DLI) for chemorefractory advanced nasopharyngeal carcinoma (NPC)
Authors: H. C. Toh, E. H. Tan, C. H. Thng, S. P. Yap, K. M. Lee, Y. P. Phoon, S. Chua, Y. Soe, S. W. Hee, L. Sun
Journal: Journal of Clinical Oncology (2006)

2549 Background: There is emerging clinical evidence for T cell immunotherapy in NPC. We report a NMBSCT regimen that induced mixed chimerism for DLI to potentially achieve a graft-versus-tumour effect (GVT) in NPC. Methods: 15 patients with advanced pretreated NPC were accrued to this prospective clinical trial. Our regimen comprised IV cyclophosphamide 50 mg/kg on day-5,-4,-3 and IV thymoglobuline on day-1, +1, +2 and +3 (n = 9) and then revised to IV thymoglobuline day-1, +1, +2, +3 (n = 6). Thymic radiation was given on day-1. G-CSF mobilized HLA-matched (n = 14) and 1-antigen-mismatched (n = 1) sibling PBSC were infused. DLI was initiated following taper of prophylactic cyclosporine (CyA). Results: Median age (n =15) was 49 yrs, median no. of metastatic organ sites was 3, mean no. of prior chemotherapy was 4 (range 2 - 8) and 14/15 had prior radiation. Median time to engraftment was 13 days and hospital stay was 17 days. Complete removal of prophylactic CyA was achieved for all patients at a median of day +28. DLI was given in 14 patients (median = 2, range 1 to 6). 4 patients were later re-started on GVHD immunosuppressive therapy. Two (13.3%) patients had acute GVHD (one Grade II and one fatal case who died on day+91). 3 patients developed chronic GVHD (20%), all controlled with short courses of standard immunosuppressive treatment. 11/15 died of PD, and 2/15 died from sepsis. 100-day TRM was 6.6%. 3/9 patients had donor graft loss. 6/6 patients on the revised protocol had stable and/or full donor chimerism. CMV antigenemia was 9/9 for the first regimen and 3/6 for the revised regimen (p = 0.044). Tumor response (RECIST) confirmed 40% PR, 33.3% SD and 40% PD, for a disease control rate of 73.3%. &gt; day+100 anti-tumor response were observed in 5/15 patients (33.3%), implicating a GVT effect. 1 patient achieved a delayed PR on day+111 with stable donor chimerism of 19%. The longest surviving patient (36.5 mths) with multiple nodal, bone and lung metastasis achieved full donor chimerism and further tumor shrinkage at 8 mths post-NMBSCT. Conclusions: GVT is achievable with NMBSCT ± DLI in Stage IV NPC patients with a high disease control rate and acceptable GVHD. Early complete removal of prophylactic CyA was possible in all 15 patients. No significant financial relationships to disclose.